Management of Negative Myoclonus
For a patient presenting with negative myoclonus, immediately initiate valproate as first-line therapy while simultaneously conducting video-EEG monitoring to confirm the diagnosis and identify the epileptiform discharge pattern, as negative myoclonus is fundamentally an epileptic phenomenon requiring antiseizure medication.
Diagnostic Evaluation
Essential Neurophysiological Testing
Negative myoclonus is frequently missed on clinical examination alone because it often follows positive myoclonus, making the silent period difficult to detect 1. You need:
- Video-EEG with polygraphic recordings: This is non-negotiable. Have the patient stand with upper limbs outstretched during recording to provoke the phenomenon 2
- Look for contralateral central-parietal epileptiform discharges on ictal EEG - this is the characteristic pattern for upper limb involvement 3, 2
- Check for midline discharges if lower limbs are involved 3
- Measure silent period length: Typically ranges 88-194 ms 1
- Perform jerk-locked back-averaging and cortico-muscular coherence analysis to confirm cortical origin 1
Critical Clinical Assessment Points
Review ALL medications immediately - particularly look for:
Assess for ESES (electrical status epilepticus during sleep) - present in 76% of pediatric cases and dramatically changes management 3
Evaluate fall frequency and motor function - negative myoclonus correlates with more severe motor phenotype (100% fall rate vs 37.5% in those without) 1
Obtain brain MRI to evaluate for structural abnormalities, particularly focal cortical dysplasia, especially if refractory to initial treatment 3
Treatment Algorithm
First-Line Management
Start valproate immediately 3, 2. This is supported by the strongest pediatric evidence showing:
- Effective control in non-ESES patients
- Resolution of oxcarbazepine-induced negative myoclonus when switched to valproate 3
- Successful control in benign epilepsy with centrotemporal spikes presenting as isolated negative myoclonus 2
Alternative first-line option: Levetiracetam 2 - particularly useful if valproate is contraindicated
Critical Medication Pitfall
Avoid or discontinue oxcarbazepine - it can paradoxically worsen epileptic negative myoclonus 3. If the patient is already on oxcarbazepine, transition to valproate.
Second-Line for ESES-Positive Cases
If ESES is present on EEG (13/17 cases in the largest pediatric series) 3:
- Try ASM optimization first (responds in ~23% of ESES cases)
- If no response, initiate methylprednisolone pulse therapy - this is indicated for ESES unresponsive to ASMs 3
- Be prepared for steroid dependency - 44% of patients relapse upon steroid withdrawal 3
Third-Line for Refractory Cases
- Ketogenic diet - showed good response in steroid-refractory ESES with negative myoclonus 3
- Surgical evaluation if structural lesion (particularly focal cortical dysplasia type IIa) is identified - one case achieved complete remission post-resection 3
Drug-Induced Cases
If negative myoclonus is drug-induced (pregabalin, SSRIs):
- Discontinue the offending agent immediately
- Administer lorazepam IV for acute symptom control 4
- Symptoms typically resolve within 2 days of discontinuation 4, 5
- EEG normalizes concurrently with clinical improvement 5
Key Clinical Pearls
The female predominance (12:5 ratio) in epileptic negative myoclonus suggests sex-related factors may influence expression 3. This is important for counseling and may have implications for hormonal influences on seizure control.
Negative myoclonus can be the sole presenting symptom of epilepsy (occurred in 2/17 pediatric cases) 3, so don't dismiss it as a movement disorder - it requires antiseizure treatment.
The correlation between EEG discharge location and affected limb is consistent: contralateral central-parietal for upper limbs, midline for lower limbs 3. This helps confirm the diagnosis and localize the epileptic focus.